Conference Details - Overview
Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer
Gaylord National Hotel & Convention Center
National Harbor, MD
October 1, 2010
Conference Overview
Overview and Purpose
The Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer symposium focuses on 3 controversial aspects of breast cancer therapy, highlighting recent advances in molecular assay–based risk assessment for node-negative and node-positive disease, therapeutic approaches to early-stage and advanced triple-negative breast cancer, and optimal strategies for the management of patients with early-stage or metastatic HER2+ breast cancer. Leading experts in the field of breast cancer will present cases illustrating areas of debate followed by their perspectives on the interpretation and application of recent clinical data and guidelines in order to increase the ability of participants to apply new data to their clinical practice and improve patient care.
Not an official event of the ASCO Breast Cancer Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the ASCO Breast Cancer Symposium.
Target Audience
This educational program is directed toward medical oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
Learning Objectives
At the conclusion of this symposium, you should be able to:
- Evaluate the utility of gene profiling tools in assessing recurrence risk and predicting benefit from adjuvant chemotherapy to assist decision making for early-stage breast cancer
- Examine the adjuvant chemotherapy options for patients with early-stage, triple-negative breast cancer
- Discuss the latest clinical data on adjuvant HER2-targeted therapy, including patient selection and management of associated toxicities
- Assess the efficacy and safety of cytotoxic agents and targeted therapies, or combinations of both, in patients with advanced triple-negative breast cancer
- Review standard and novel therapeutic options for patients with HER2-overexpressing metastatic breast cancer, including combinatorial therapies and options beyond progression on standard therapy
- Guide patients with breast cancer to promising clinical trials
Meeting information is accurate at the time of posting.
170-2588